Navigation Links
CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
Date:7/11/2012

ATLANTA, July 11, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that 2012 second quarter financial results will be released on Tuesday, July, 31, 2012.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive officer of CryoLife, Inc.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m.  A replay of the teleconference will be available July 31 through August 7 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415.  The account number for the replay is 244 and the conference number is 397253.

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife website at www.cryolife.com and selecting the heading Webcasts & Presentations.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada.  CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia.  CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  CryoLife's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of cardiovascular disease and the sale of devices that treat severe angina.  Its market leading FDA-approved Holmium: YAG laser system and single use fiber-optic delivery systems are used to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  In addition, CryoLife's subsidiary Hemosphere, Inc. markets the HeRO Graft, which is a solution for end-stage renal disease in certain hemodialysis patients.  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community.  CryoLife's BioFoam Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. 

For additional information about the company, visit CryoLife's website: http://www.cryolife.com

Contacts:

CryoLife

D. Ashley Lee

Executive Vice President, Chief Financial Officer
and Chief Operating
Officer Phone: 770-419-3355

The Ruth Group

Nick Laudico / Zack Kubow

646-536-7030 / 7020

nlaudico@theruthgroup.com

zkubow@theruthgroup.com


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
2. CryoLife Completes Acquisition of Hemosphere
3. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
4. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
5. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
6. Genova Diagnostics, Inc. Announces the Acquisition of Metametrix, Inc.
7. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
8. Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
9. Elsevier Announces New Editor-In-Chief for Neurobiology of Learning and Memory
10. Express Scripts Holding Company Announces Second Quarter 2012 Earnings Conference Call
11. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 Een app die ... zij collectief patiënten kunnen behandelen, hun kennis kunnen delen ... achter de nieuwe en revolutionaire MDLinking App, ontwikkeld door ... vaatchirurg dr. Hans Flu en oncologisch chirurg dr. ... beschikbaar is, wordt op dinsdag 24 mei officieel gepresenteerd ...
(Date:5/23/2016)... 23, 2016 Transparency Market Research ... Pancreatic Insufficiency Market - Global Industry Analysis, Size, Share, ... to the report, the exocrine pancreatic insufficiency market is ... 2015 to 2023 to reach US$2.85 Bn by 2023. ... characterized by the deficiency of the exocrine pancreatic enzymes, ...
(Date:5/23/2016)... 2016 Non-invasive diagnostic test realizes ... diseases; ,Technology to be presented at Yissum’s booth, at ... Development Company of the Hebrew University of Jerusalem ... with Aurum Ventures MKI, the technology investment arm of ... diagnostic approach for early detection of multiple diseases by ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... Center at Sentara Northern Virginia Medical Center located in Woodbridge, VA. The ... surgical services into a single site. , The new 2 story building houses ...
(Date:5/24/2016)... ... May 24, 2016 , ... Mental health watchdog Citizens Commission on ... and renowned professor of psychiatry Thomas Szasz, is continuing its protest against the use ... Death” exhibit in Atlanta, Georgia. The opening of the exhibit follows CCHR’s recent protest ...
(Date:5/24/2016)... ... 24, 2016 , ... Loma Linda University Health (LLUH) has officially broken ground ... Hospital. Over 3,000 people looked on as the shovels hit the dirt at the ... , During the program, Richard H. Hart, MD, DrPH, president, LLUH, recapped the ...
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades of experience, ... job, ensuring the best suited solution to meet regulatory requirements. Their professional staff ... lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and ...
(Date:5/24/2016)... ... May 24, 2016 , ... Growing in popularity, more and more people ... are available and easily accessible. Whether someone chooses to cut gluten out of their ... diet, King Kullen Grocery stocks their shelves with many different gluten-free products all year ...
Breaking Medicine News(10 mins):